United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Chevy Chase Trust Holdings LLC

Chevy Chase Trust Holdings LLC increased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 106.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 23,049 shares of the biotechnology company’s stock after purchasing an additional 11,890 shares during the period. Chevy Chase Trust Holdings LLC owned 0.05% of United Therapeutics worth $8,260,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in UTHR. ClariVest Asset Management LLC boosted its position in shares of United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after buying an additional 42 shares during the period. V Square Quantitative Management LLC acquired a new position in United Therapeutics during the 2nd quarter worth approximately $30,000. Innealta Capital LLC purchased a new position in United Therapeutics in the 2nd quarter worth approximately $33,000. USA Financial Formulas acquired a new stake in United Therapeutics in the third quarter valued at approximately $33,000. Finally, Brooklyn Investment Group purchased a new stake in shares of United Therapeutics during the third quarter valued at approximately $33,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO James Edgemond sold 7,796 shares of United Therapeutics stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $354.04, for a total transaction of $2,760,095.84. Following the sale, the chief financial officer now owns 4,264 shares of the company’s stock, valued at approximately $1,509,626.56. The trade was a 64.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Christopher Causey sold 510 shares of the stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the transaction, the director now directly owns 3,675 shares of the company’s stock, valued at $1,384,115.25. This trade represents a 12.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 119,442 shares of company stock valued at $44,577,770. Insiders own 11.90% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on UTHR. Argus upped their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Wells Fargo & Company upped their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. Jefferies Financial Group lifted their target price on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Finally, HC Wainwright lifted their price objective on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $370.86.

United Therapeutics Price Performance

UTHR stock opened at $374.37 on Friday. The firm has a fifty day moving average price of $368.58 and a two-hundred day moving average price of $337.70. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82. The firm has a market cap of $16.72 billion, a price-to-earnings ratio of 16.44, a PEG ratio of 1.07 and a beta of 0.54.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same quarter in the prior year, the business earned $5.38 earnings per share. United Therapeutics’s quarterly revenue was up 22.9% on a year-over-year basis. As a group, analysts expect that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.